Скачать с ютуб Organoids: A Revolutionary New Tool for Drug Screening в хорошем качестве

Organoids: A Revolutionary New Tool for Drug Screening

Presented By: Rekha Pal, PhD - Director, Scientific Engagement, Crown Bioscience, Inc. Speaker Biography: Rekha is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her Ph.D. in Biochemistry from Central Drug Research Institute, India. She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient's blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment. She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP's phase I/II clinical trials for colon and breast cancer. Webinar: Organoids: A Revolutionary New Tool for Drug Screening Webinar Abstract: “The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo genetic drift over time due to adapting to in vitro growth, thus showing limited relevance to the human disease. Interpatient tumor heterogeneity is also a major hurdle with standard in vitro models failing to recapitulate this variability. Patient-derived xenografts are the gold standard preclinical models for their proven translatability to the human disease but can be costly and time consuming to generate and maintain. The Hubrecht Organoid Technology (HUB) has pioneered the development of tumor organoids, a revolutionary patient-derived 3D in vitro system that recapitulates the genomic, morphological, and pathophysiological characteristics of their parental tumor. HUB organoids provide highly clinically relevant 3D in vitro models for oncology drug development. To overcome the limitation imposed by sourcing patient material for organoid preclinical development PDX can be used as a source of human tumor tissue leading to a patient-relevant matched in vitro/in vivo platform for oncology drug screening.” Learning bullets: 1. Find out why HUB organoids are considered best in class systems 2. Understand how organoids are revolutionizing oncology drug development 3. Learn about how patient-derived xenografts (PDX) can be leveraged to develop the largest organoid library for oncology drug discovery Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-even...) 2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/virtual-even...) 3. Click Here to get your PACE credits (Expiration date – January 01, 2022 06:00 AM): https://www.labroots.com/credit/pace-... LabRoots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc